Infliximab

Infliximab Reactions 1704, p199 - 2 Jun 2018 Drug hypersensitivity reactions and infections: 4 case reports In a study of 12 patients from the STAT registry, four patients (three women and one man), aged 43–60 years, were described. A woman developed a drug-hypersensitivity reaction during treatment with infliximab. The remaining three patients developed infections during treatment with infliximab [doses, durations of treatment to reactions onsets and outcomes not stated]. A 49-year-old woman (Patient 7), who was diagnosed with neurosarcoidosis with severe localisation, also had upper respiratory tract involvement presenting with crusting. She had received treatment with unspecified corticosteroids and immunosuppressants initially. She started receiving treatment with IV infliximab infusion. She was scheduled to receive the infliximab infusions at weeks 0, 2 and 6 followed by every 4–8 weeks. She also received an unspecified immunosuppressant concomitantly. Subsequently, she developed an infection due to the infliximab treatment. Her infliximab therapy was then discontinued permanently. A 43-year-old man (Patient 8), who was diagnosed with neurosarcoidosis with severe localisation, also had upper respiratory tract involvement presenting with nasal obstruction. He had received treatment with unspecified corticosteroids and immunosuppressants initially. He started receiving treatment with IV infliximab infusion. He was scheduled to receive the infliximab infusions at weeks 0, 2 and 6 followed by every 4–8 weeks. He also received an unspecified immunosuppressant concomitantly. Subsequently, he developed iterative infections due to the infliximab treatment. His infliximab therapy required frequent temporary discontinuation due to the iterative infections. However, he experienced relapse of sarcoidosis during each temporary infliximab discontinuation. Thereafter, the infliximab treatment was discontinued permanently. A 50-year-old woman (Patient 11), who was diagnosed with sarcoidosis with severe localisation and lupus perio, also had upper respiratory tract involvement presenting with nasal obstruction. She had received treatment with unspecified corticosteroids and immunosuppressants initially. She started receiving treatment with IV infliximab infusion. She was scheduled to receive the infliximab infusions at weeks 0, 2 and 6 followed by every 4–8 weeks. She also received an unspecified immunosuppressant concomitantly. Subsequently, she developed an infection due to the infliximab treatment. Her infliximab therapy was then discontinued A 60-year-old woman (Patient 12), who was diagnosed with sarcoidosis with severe localisation and interstitial pneumonia, also had upper respiratory tract involvement presenting with nasal symptoms. She had received treatment with unspecified corticosteroids and immunosuppressants initially. She started receiving treatment with IV infliximab infusion. She was scheduled to receive the infliximab infusions at weeks 0, 2 and 6 followed by every 4–8 weeks. She also received an unspecified immunosuppressant concomitantly. Subsequently, she developed a severe drug hypersensitivity reaction with symptoms of fever and shivering during the infliximab treatment. The infliximab treatment was then discontinued without relapse of the sarcoidosis. Author comment: "3 patients presented infections (patient #7, #8 and #11)". "Infections were the main adverse effect of [infliximab]". "Drug hypersensitivity reactions occurred in one case." Barba T, et al. Efficacy and safety of infliximab therapy in refractory upper respiratory tract sarcoidosis: Experience from the STAT registry. Sarcoidosis Vasculitis and Diffuse Lung Diseases 34: 343-351, No. 4, 01 Feb 2017. Available from: URL: http://www.mattioli1885journals.com/index.php/sarcoidosis/article/ view/5817 - France 803322986 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Infliximab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/infliximab-Tjpk1QCNr5
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46842-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p199 - 2 Jun 2018 Drug hypersensitivity reactions and infections: 4 case reports In a study of 12 patients from the STAT registry, four patients (three women and one man), aged 43–60 years, were described. A woman developed a drug-hypersensitivity reaction during treatment with infliximab. The remaining three patients developed infections during treatment with infliximab [doses, durations of treatment to reactions onsets and outcomes not stated]. A 49-year-old woman (Patient 7), who was diagnosed with neurosarcoidosis with severe localisation, also had upper respiratory tract involvement presenting with crusting. She had received treatment with unspecified corticosteroids and immunosuppressants initially. She started receiving treatment with IV infliximab infusion. She was scheduled to receive the infliximab infusions at weeks 0, 2 and 6 followed by every 4–8 weeks. She also received an unspecified immunosuppressant concomitantly. Subsequently, she developed an infection due to the infliximab treatment. Her infliximab therapy was then discontinued permanently. A 43-year-old man (Patient 8), who was diagnosed with neurosarcoidosis with severe localisation, also had upper respiratory tract involvement presenting with nasal obstruction. He had received treatment with unspecified corticosteroids and immunosuppressants initially. He started receiving treatment with IV infliximab infusion. He was scheduled to receive the infliximab infusions at weeks 0, 2 and 6 followed by every 4–8 weeks. He also received an unspecified immunosuppressant concomitantly. Subsequently, he developed iterative infections due to the infliximab treatment. His infliximab therapy required frequent temporary discontinuation due to the iterative infections. However, he experienced relapse of sarcoidosis during each temporary infliximab discontinuation. Thereafter, the infliximab treatment was discontinued permanently. A 50-year-old woman (Patient 11), who was diagnosed with sarcoidosis with severe localisation and lupus perio, also had upper respiratory tract involvement presenting with nasal obstruction. She had received treatment with unspecified corticosteroids and immunosuppressants initially. She started receiving treatment with IV infliximab infusion. She was scheduled to receive the infliximab infusions at weeks 0, 2 and 6 followed by every 4–8 weeks. She also received an unspecified immunosuppressant concomitantly. Subsequently, she developed an infection due to the infliximab treatment. Her infliximab therapy was then discontinued A 60-year-old woman (Patient 12), who was diagnosed with sarcoidosis with severe localisation and interstitial pneumonia, also had upper respiratory tract involvement presenting with nasal symptoms. She had received treatment with unspecified corticosteroids and immunosuppressants initially. She started receiving treatment with IV infliximab infusion. She was scheduled to receive the infliximab infusions at weeks 0, 2 and 6 followed by every 4–8 weeks. She also received an unspecified immunosuppressant concomitantly. Subsequently, she developed a severe drug hypersensitivity reaction with symptoms of fever and shivering during the infliximab treatment. The infliximab treatment was then discontinued without relapse of the sarcoidosis. Author comment: "3 patients presented infections (patient #7, #8 and #11)". "Infections were the main adverse effect of [infliximab]". "Drug hypersensitivity reactions occurred in one case." Barba T, et al. Efficacy and safety of infliximab therapy in refractory upper respiratory tract sarcoidosis: Experience from the STAT registry. Sarcoidosis Vasculitis and Diffuse Lung Diseases 34: 343-351, No. 4, 01 Feb 2017. Available from: URL: http://www.mattioli1885journals.com/index.php/sarcoidosis/article/ view/5817 - France 803322986 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off